Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies across many chronic inflammatory diseases, but recently this promise has been overshadowed by questions regarding associated cardiovascular and cancer risk emerging from the ORAL Surveillance phase 3b/4 post-marketing...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Victor, Kragstrup, Tue W., McMaster, Christopher, Reid, Pankti, Singh, Namrata, Haysen, Stine R., Robinson, Philip C., Liew, David F. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Therapy in Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632271/
https://www.ncbi.nlm.nih.gov/pubmed/37490213
http://dx.doi.org/10.1007/s40264-023-01333-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632271/
https://www.ncbi.nlm.nih.gov/pubmed/37490213
http://dx.doi.org/10.1007/s40264-023-01333-0

Ejemplares similares